Skip to main content

BioWorld - Elsalys looks to cross goal line in SR-aGVHD on positive long-term OS

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac) showed clinical benefit during long-term follow-up of up to 8.5 years in individuals treated in the phase III study in acute steroid-resistant graft-vs.-host disease (SR-aGVHD). The positive overall survival (OS) outcome in the long-term analysis positions the Lyon, France-based company for a regulatory filing in the EU next year and puts discussions with commercial partners on the front burner – admirable achievements for a company of just 16 employees that’s raised less than €20 million (US$22.8 million).


Subcribe to our newsletter

Copyright 2021 ElsaLys Biotech SA

twitter    linkedin

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.